Yale Team Shares Importance of Lung Cancer Screening at Community Event at Q House in New Haven.
- August 10, 2023Source: OncLive
Paul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.
- August 03, 2023
A research team co-led by Dr. Katerina Politi found how mSWI/SNF complexes mediate resistance of lung adenocarcinomas to osimertinib and other tyrosine kinase inhibitors.
- June 29, 2023Source: The Hill
DIEP (deep inferior epigastric perforator), in which abdominal tissue is transplanted to the chest without using abdominal muscle, may soon be less available. Why? The Centers for Medicare and Medicaid Services (CMS) is planning to eliminate the billing codes for this and other specialized breast reconstruction procedures on Dec. 31, 2024. This should not be the case: women facing breast cancer need all the best reconstruction options readily available. This is deeply personal for me.
- May 25, 2023
American Society for Investigative Pathology Features Katerina Politi, PhD, During Women in Pathology MonthSource: American Society for Investigative Pathology
The American Society for Investigative Pathology features Katerina Politi, PhD, Associate Professor of Pathology, during Women in Pathology Month.
- December 13, 2022
Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung CancerSource: ASCO Daily News
Targeted therapies and immune checkpoint inhibitors have transformed the treatment landscape for non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have contributed to an overall decline in lung cancer–related mortality, and as they move into the early-stage setting, more dramatic improvements in outcomes are expected. However, combatting TKI resistance in NSCLC is largely an unmet challenge. Tissue next-generation sequencing and plasma circulating tumor DNA–based assays have emerged as concurrent methods to identify targetable mechanisms of resistance to TKIs at the time of clinical progression, while antibody-drug conjugates represent a promising therapeutic class for the treatment of TKI-resistant NSCLC.
- December 04, 2022
In a new study, Yale Cancer Center researchers found molecular explanations for why some lung tumors respond better to certain drugs than others. The research should help improve drug selection for lung cancer patients with different mutations in the EGF receptor, using a precision medicine approach to treatment.
- November 30, 2022
Dr. Stockhammer received the Distinguished Young Investigator Research Award at this year’s EGFR Resisters Research Summit in Chicago, IL.
- June 02, 2022
Irina Krykbaeva, a recent PhD graduate in the Department of Pathology at Yale School of Medicine, is the winner of the 2022 Milton C. Winternitz Prize in Pathology. The prize is awarded annually to the student who, in the opinion of the department faculty and staff, has done outstanding work in the course.
- April 12, 2022
Yale Pathology Meets in Madison for Department Retreat; First In-Person Gathering Since Pandemic Began
Faculty and staff of Yale Pathology went to the Water’s Edge Resort in Madison on April 2 for a full-day retreat, the department’s first in-person gathering since the coronavirus pandemic began more than two years ago.